Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Travere Therapeutics (NASDAQ: TVTX) has announced inducement equity grants for ten new employees, approved by the Compensation Committee of its Board of Directors on February 10, 2025. The grants include 36,000 shares of stock options and 79,100 shares of restricted stock units (RSUs).
The stock options, priced at $21.10 per share, are non-qualified with a 10-year term. They vest over four years, with 25% vesting after one year and the remaining 75% vesting monthly over 36 months. The RSUs also follow a four-year vesting schedule, with 25% vesting annually. Both grants require continued employment with Travere and were issued outside the 2018 Equity Incentive Plan under Nasdaq Listing Rule 5635(c)(4).
Travere Therapeutics (NASDAQ: TVTX) ha annunciato concessioni di azioni per dieci nuovi dipendenti, approvate dal Comitato per la Retribuzione del Consiglio di Amministrazione il 10 febbraio 2025. Le concessioni includono 36.000 azioni di opzioni su azioni e 79.100 azioni di unità di azioni vincolate (RSU).
Le opzioni su azioni, con un prezzo di $21.10 per azione, sono non qualificate e hanno una durata di 10 anni. Si maturano in quattro anni, con il 25% che matura dopo un anno e il restante 75% che matura mensilmente per 36 mesi. Anche le RSU seguono un programma di maturazione di quattro anni, con il 25% che matura annualmente. Entrambe le concessioni richiedono un impiego continuativo con Travere e sono state emesse al di fuori del Piano di Incentivazione azionaria del 2018 secondo la Regola di Quotazione Nasdaq 5635(c)(4).
Travere Therapeutics (NASDAQ: TVTX) ha anunciado concesiones de acciones para diez nuevos empleados, aprobadas por el Comité de Compensación de su Junta Directiva el 10 de febrero de 2025. Las concesiones incluyen 36,000 acciones de opciones sobre acciones y 79,100 acciones de unidades de acciones restringidas (RSUs).
Las opciones sobre acciones, con un precio de $21.10 por acción, son no calificadas y tienen un plazo de 10 años. Se consolidan en cuatro años, con el 25% consolidándose después de un año y el 75% restante consolidándose mensualmente durante 36 meses. Las RSUs también siguen un calendario de consolidación de cuatro años, con el 25% consolidándose anualmente. Ambas concesiones requieren empleo continuo con Travere y se emitieron fuera del Plan de Incentivo de Capital de 2018 bajo la Regla de Cotización Nasdaq 5635(c)(4).
Travere Therapeutics (NASDAQ: TVTX)는 2025년 2월 10일 이사회 보상위원회에서 승인된 10명의 신규 직원에 대한 주식 보상 계획을 발표했습니다. 이 보상에는 36,000주의 주식 옵션과 79,100주의 제한된 주식 단위(RSU)가 포함됩니다.
주식 옵션은 주당 $21.10의 가격으로 비자격이며 10년의 기간을 가집니다. 옵션은 4년에 걸쳐 분할되어 1년 후에 25%가 부여되고 나머지 75%는 36개월 동안 월별로 부여됩니다. RSU도 4년의 분할 일정에 따라 25%가 매년 부여됩니다. 두 가지 보상 모두 Travere와의 지속적인 고용을 요구하며, Nasdaq 상장 규정 5635(c)(4) 아래 2018년 주식 인센티브 계획 외부에서 발행되었습니다.
Travere Therapeutics (NASDAQ: TVTX) a annoncé des attributions d'actions pour dix nouveaux employés, approuvées par le Comité de Rémunération de son Conseil d'Administration le 10 février 2025. Les attributions comprennent 36.000 actions d'options sur actions et 79.100 actions d'unités d'actions restreintes (RSUs).
Les options sur actions, au prix de $21.10 par action, ne sont pas qualifiées et ont une durée de 10 ans. Elles se vesteront sur quatre ans, avec 25% se vesteront après un an et les 75% restants se vesteront mensuellement sur 36 mois. Les RSUs suivent également un calendrier de vesting de quatre ans, avec 25% se vesteront annuellement. Les deux attributions nécessitent un emploi continu avec Travere et ont été émises en dehors du Plan d'Incentive en Actions de 2018, conformément à la Règle de Cotation Nasdaq 5635(c)(4).
Travere Therapeutics (NASDAQ: TVTX) hat am 10. Februar 2025, genehmigt durch den Vergütungsausschuss des Vorstands, Aktienoptionen für zehn neue Mitarbeiter angekündigt. Die Vergaben umfassen 36.000 Aktien von Optionen und 79.100 Aktien von eingeschränkten Aktieneinheiten (RSUs).
Die Optionen haben einen Preis von $21.10 pro Aktie, sind nicht qualifiziert und haben eine Laufzeit von 10 Jahren. Sie werden über vier Jahre vestiert, wobei 25% nach einem Jahr und die verbleibenden 75% monatlich über 36 Monate vestiert werden. Auch die RSUs folgen einem vierjährigen Vesting-Plan, wobei 25% jährlich vestiert werden. Beide Vergaben erfordern eine fortdauernde Anstellung bei Travere und wurden außerhalb des Equity Incentive Plans von 2018 gemäß der Nasdaq-Listing-Regel 5635(c)(4) ausgegeben.
- Company demonstrates ability to attract new talent with equity compensation
- Structured vesting schedule helps retain employees over long-term (4 years)
- Potential dilution of existing shareholders through new equity grants of 115,100 shares
SAN DIEGO, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on February 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 115,100 shares of its common stock to ten new employees, consisting of inducement stock options to purchase an aggregate of 36,000 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 79,100 shares of its common stock. These inducement stock options and inducement RSUs are subject to the terms of Travere’s 2018 Equity Incentive Plan (“2018 Plan”) but were granted outside of the 2018 Plan and were granted as inducements material to the new employees entering into employment with Travere in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of
The RSUs vest over four years, with
About Travere Therapeutics
At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com.
Contact Info
| Media: 888-969-7879 mediarelations@travere.com | Investors: 888-969-7879 IR@travere.com |
FAQ
How many shares were granted in TVTX's February 2025 inducement grants?
What is the exercise price for TVTX's February 2025 inducement stock options?
What is the vesting schedule for TVTX's February 2025 inducement RSUs?
How long is the vesting period for TVTX's February 2025 stock options?
How many new employees received TVTX's February 2025 inducement grants?
